DUBLIN–(BUSINESS WIRE)–The “North America Superdisintegrants Market to 2027 – Regional Analysis and Forecasts by Type; Formulation; Therapeutic Area, and Country” report has been added to ResearchAndMarkets.com’s offering.
The North American superdisintegrants market is growing primarily due to the increasing prevalence of neurological diseases and the benefits offered by generic drugs which are boosting the market. Restraining factors, such as pricing pressure on drug manufacturers, are likely to damage the growth of the market in the coming years. On the other hand, growing medical tourism in Mexico is expected to have a positive impact on the growth of the North American superdisintegrants market in the coming years.
The superdisintegrants are the agents that are mixed in the tablets to intensify the breakup of the tablet into small fragments in aqueous conditions, thereby boosting the release of the drug into the body. In previous years, superdisintegrants have gained the attention of the pharmaceutical industry as they increase the solubility of active pharmaceutical ingredient (API) in the body by raising the absorption of the drug in the body due to which the bioavailability of drugs also increases. The superdisintegrant agent is used in tablets and capsules.
Generic drugs refer to qualitative and quantitative compositions of active components whose bioequivalence has been demonstrated by suitable bioavailability studies. Cost efficiency is the prominent factor that is driving the acceptance and adoption of generic drugs across the world. For instance, according to the study published in Journal of Pharmaceutical Health Care and Sciences (2015), nearly 50.0-60.0% of drug use across the world was of generic drugs. Certain benefits such as superior treatment outcomes, cost benefits, and easy availability played a major part in higher consumption of generic medications. Such higher consumption of generic medications is directly correlated to increased manufacturing of drugs. Moreover, increasing popularity of orally disintegrating drugs is likely to drive the usage of superdisintegrants in generic drugs, which will ultimately drive the growth of the global superdisintegrants market during the forecast period. Additionally, the majority of the governments across the world are also implementing strategic policies to encourage the use of generic drugs. As generic drugs are cheaper by about 30-80%, the government is focusing to increase its adoption with an aim of expanding the reach of drugs to every financial class.
In 2019, the synthetic superdisintegrants segment accounted for the largest market share in the North American superdisintegrants market. The growth of the synthetic superdisintegrants segment is expected to grow due to the wide consumption of these superdisintegrants in numerous pharmaceutical drug formulations owing to the benefits offered such as efficiency at lesser concentrations as compared to starch and a smaller effect on the compressibility and flow ability of the dosage form. These factors are increasing the demand of synthetic superdisintegrants in the forecast period.
In 2019, the tablets segment held the most significant market share of the superdisintegrants market by formulation. This segment is also anticipated to hold a considerable portion of the market in 2027, owing to the high rate of tablet manufacturing and increasing number of hospital visits are also projected to drive the consumption of tablets. The segment is also anticipated to witness growth at a significant rate during the forecast period.
In 2019, the gastrointestinal diseases segment held the most significant market share of the superdisintegrants market by the therapeutic area. This segment is also anticipated to hold a considerable portion of the market in 2027, owing to the high prevalence of gastrointestinal conditions and increasing adoption of OTC drugs for gastrointestinal conditions are anticipated to witness growth at a significant rate during the forecast period.
Key Topics Covered:
1. Introduction
2. North America Superdisintegrants Market- Key Takeaways
3. North America Superdisintegrants Market – Market Landscape
4. North America Superdisintegrants Market – Key Market Dynamics
5. Superdisintegrants Market – North America Analysis
5.1 North America Superdisintegrants Market Revenue Forecasts and Analysis
5.2 Positioning of Key Players
6. North America Superdisintegrants Market Analysis And Forecasts To 2027 – Type
6.1 Overview
6.2 North America Superdisintegrants Market, By Type 2019 & 2027 (%)
6.3 Synthetic Superdisintegrants
6.4 Natural Superdisintegrants
6.5 Other Superdisintegrants
7. North America Superdisintegrants Market Analysis- By Formulation
7.1 Overview
7.2 North America Superdisintegrants Market, By Formulation 2019 & 2027 (%)
7.3 Tablets
7.4 Capsules
8. North America Superdisintegrants Market Analysis- By Therapeutic Area
8.1 Overview
8.2 North America Superdisintegrants Market, By Therapeutic Area 2019 & 2027 (%)
8.3 Neurological Diseases
8.4 Gastrointestinal Diseases
8.5 Oncology
8.6 Inflammatory Diseases
8.7 Infectious Diseases
8.8 Cardiovascular Diseases
9. Superdisintegrants Market Revenue And Forecasts To 2027 – Geographical Analysis
10. North America Superdisintegrants Market- Industry Landscape
11. Key Company Profiles
- Ashland
- BASF SE
- DowDupont Inc.
- JRS PHARMA
- COREL PHARMA CHEM
- Roquette Frres
- Asahi Kasei Corporation
- Merck KGaA
- Avantor, Inc.
- DFE Pharma
For more information about this report visit https://www.researchandmarkets.com/r/tovuvl
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900